Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia

被引：72
作者：
Ghia, Paolo [1 ,2 ]
Scarfo, Lydia [1 ,2 ]
Perez, Susan [3 ]
Pathiraja, Kumudu [3 ]
Derosier, Martha [3 ]
Small, Karen [3 ]
Sisk, Christine McCrary [3 ]
Patton, Nigel [4 ]
机构：
[1] Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy
[2] IRCCS Ist Sci San Raffaele, Milan, Italy
[3] Merck & Co Inc, Kenilworth, NJ USA
[4] Auckland City Hosp, Auckland, New Zealand
来源：
BLOOD | 2017年 / 129卷 / 13期
关键词：
DEPENDENT KINASE INHIBITOR; SCH; 727965; CANCER; FLAVOPIRIDOL; FLUDARABINE; CELLS; MALIGNANCIES; APOPTOSIS; IBRUTINIB; SCHEDULE;
D O I：
10.1182/blood-2016-10-748210
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1876 / 1878
页数：3
相关论文
共 50 条
[41]   Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients [J].
Osterborg, Anders ;
Wierda, William G. ;
Mayer, Jiri ;
Hess, Georg ;
Hillmen, Peter ;
Schetelig, Johannes ;
Schuh, Anna ;
Smolej, Lukas ;
Beck, Christian ;
Dreyfus, Brigitte ;
Hellman, Andrzej ;
Kozlowski, Piotr ;
Pfreundschuh, Michael ;
Rizzi, Rita ;
Spacek, Martin ;
Phillips, Jennifer L. ;
Gupta, Ira V. ;
Williams, Vanessa ;
Jewell, Roxanne C. ;
Nebot, Noelia ;
Lisby, Steen ;
Dyer, Martin J. S. .
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (01) :40-49
[42]   Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis [J].
Xu, Wei ;
Yang, Shenmiao ;
Zhou, Keshu ;
Pan, Ling ;
Li, Zengjun ;
Gao, Sujun ;
Zhou, Daobin ;
Hu, Jianda ;
Feng, Ru ;
Huang, Haiwen ;
Wang, Tingyu ;
Li, Dengju ;
Ji, Meng ;
Guo, Haiyi ;
Zhao, Xia ;
Wu, Binghao ;
Yu, Yiling ;
Wang, Yu ;
Huang, Jane ;
Novotny, William ;
Li, Jianyong .
LEUKEMIA & LYMPHOMA, 2023, 64 (03) :712-716
[43]   Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies [J].
Rainone, Michael ;
Siddiqi, Tanya .
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2022, 17 (01) :39-45
[44]   ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma [J].
Hillmen, Peter ;
Brown, Jennifer R. ;
Eichhorst, Barbara F. ;
Lamanna, Nicole ;
O'Brien, Susan M. ;
Qiu, Lugui ;
Salmi, Tommi ;
Hilger, James ;
Wu, Kenneth ;
Cohen, Aileen ;
Huang, Jane ;
Tam, Constantine S. .
FUTURE ONCOLOGY, 2020, 16 (10) :517-523
[45]   Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies [J].
Michael Rainone ;
Tanya Siddiqi .
Current Hematologic Malignancy Reports, 2022, 17 :39-45
[46]   Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial [J].
Robak, Tadeusz ;
Warzocha, Krzysztof ;
Babu, K. Govind ;
Kulyaba, Yaroslav ;
Kuliczkowski, Kazimierz ;
Abdulkadyrov, Kudrat ;
Loscertales, Javier ;
Kryachok, Iryna ;
Kloczko, Janusz ;
Rekhtman, Grygoriy ;
Homenda, Wojciech ;
Blonski, Jerzy Z. ;
McKeown, Astrid ;
Gorczyca, Michele M. ;
Carey, Jodi L. ;
Chang, Chai-Ni ;
Lisby, Steen ;
Gupta, Ira V. ;
Grosicki, Sebastian .
LEUKEMIA & LYMPHOMA, 2017, 58 (05) :1084-1093
[47]   Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review [J].
Islam, Prioty .
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (09) :1259-1273
[48]   Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia [J].
Sandhu, Suneet ;
Mulligan, Stephen P. .
HAEMATOLOGICA, 2015, 100 (04) :411-415
[49]   Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study [J].
Hillmen, Peter ;
Rawstron, Andy C. ;
Brock, Kristian ;
Munoz-Vicente, Samuel ;
Yates, Francesca J. ;
Bishop, Rebecca ;
Boucher, Rebecca ;
MacDonald, Donald ;
Fegan, Christopher ;
McCaig, Alison ;
Schuh, Anna ;
Pettitt, Andrew ;
Gribben, John G. ;
Patten, Piers E. M. ;
Devereux, Stephen ;
Bloor, Adrian ;
Fox, Christopher P. ;
Forconi, Francesco ;
Munir, Talha .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) :2722-+
[50]   The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL [J].
Flinn, Ian W. ;
Hillmen, Peter ;
Montillo, Marco ;
Nagy, Zsolt ;
Illes, Arpad ;
Etienne, Gabriel ;
Delgado, Julio ;
Kuss, Bryone J. ;
Tam, Constantine S. ;
Gasztonyi, Zoltan ;
Offner, Fritz ;
Lunin, Scott ;
Bosch, Francesco ;
Davids, Matthew S. ;
Lamanna, Nicole ;
Jaeger, Ulrich ;
Ghia, Paolo ;
Cymbalista, Florence ;
Portell, Craig A. ;
Skarbnik, Alan P. ;
Cashen, Amanda F. ;
Weaver, David T. ;
Kelly, Virginia M. ;
Turnbull, Barry ;
Stilgenbauer, Stephan .
BLOOD, 2018, 132 (23) :2446-2455
12345